Read in light of the results obtained through earlier studies 12, 37, 41-43, our findings point to a potential use of NAD+ precursors in conjunction with Sirt6 activation as a therapeutic option for inflammatory disorders, including anaphylaxis. The gene discussed is SIRT6; the disease is anaphylaxis.